18:19 , Jun 15, 2018 |  BC Week In Review  |  Clinical News

Lilly, AZ stop Phase III Alzheimer's trials of BACE inhibitor

Eli Lilly and Co. (NYSE:LLY) and AstraZeneca plc (LSE:AZN; NYSE:AZN) discontinued a pair of Phase III trials evaluating once-daily oral lanabecestat (AZD3293, LY3314814) to treat Alzheimer's disease after an IDMC analysis concluded that both trials...
11:29 , Jun 12, 2018 |  BC Extra  |  Clinical News

Lilly, AZ stop Phase III Alzheimer's trials of BACE inhibitor

Eli Lilly and Co. (NYSE:LLY) and AstraZeneca plc (LSE:AZN; NYSE:AZN) discontinued a pair of Phase III trials evaluating once-daily oral lanabecestat (AZD3293, LY3314814) to treat Alzheimer's disease after an IDMC analysis concluded that both trials...
17:20 , Dec 16, 2016 |  BC Week In Review  |  Company News

AstraZeneca, Eli Lilly deal

AstraZeneca and Eli Lilly partnered to co-develop MEDI1814 . AZ will receive $30 million up front and is eligible for up to $350 million in development and commercialization milestones. The mAb against beta amyloid 42...
17:50 , Dec 1, 2016 |  BC Innovations  |  Translation in Brief

Off BACE

With November’s Phase III failure of Eli Lilly and Co. ’s (NYSE:LLY) β-amyloid inhibitor solanezumab for Alzheimer’s disease, and the pharma’s announcement last week that it was abandoning efforts to submit the compound for regulatory...
07:00 , Apr 18, 2016 |  BC Week In Review  |  Clinical News

LY3314814: Phase II/III ongoing

AstraZeneca and Eli Lilly said an IDMC recommended continuation of the double-blind, placebo-controlled, international Phase II/III AMARANTH trial evaluating 20 and 50 mg oral AZD3293 once daily for 104 weeks in >2,200 patients with early...
01:23 , Apr 9, 2016 |  BC Extra  |  Clinical News

AZ, Lilly BACE inhibitor moves ahead in AD study

AstraZeneca plc (LSE:AZN; NYSE:AZN) and Eli Lilly and Co. (NYSE:LLY) said the ongoing Phase II/III AMARANTH study of AZD3293 ( LY3314814 ) to treat early Alzheimer's disease will advance to its Phase III segment on...
07:00 , Mar 24, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: β-site APP-cleaving enzyme 2 (BACE2)

Gastrointestinal disease INDICATION: Gastrointestinal (GI) dysfunction Mouse studies suggest embryonic stem cell-derived vagal neural crest progenitors could help treat Hirschsprung's disease, in which endogenous progenitors fail to migrate into the GI tract and form the...
07:00 , Mar 17, 2016 |  BC Innovations  |  Tools & Techniques

Gut re-action

A group of New York academics has developed a protocol to turn human pluripotent stem cells into gut neurons, and believes it could provide the first non-surgical treatment for Hirschsprung's disease - a rare disorder...
08:00 , Jan 14, 2016 |  BC Innovations  |  Targets & Mechanisms

Moot point in AD

The longstanding β-amyloid vs. tau debate in Alzheimer's disease (AD) might turn out to be moot, according to findings from researchers at Emory University who identified a protease, AEP , that lies upstream of both...
08:00 , Dec 15, 2014 |  BC Week In Review  |  Clinical News

LY3314814: Phase II/III started

AstraZeneca and Eli Lilly began the double-blind, placebo-controlled, international Phase II/III ANARANTH trial to evaluate 20 or 50 mg oral AZD3293 once daily for 24 months in about 1,551 patients with early AD. Earlier this...